Form 4: Abbott Laboratories Executive Vice President Mary K. Moreland Reports Stock Transactions

Executive Vice President Mary K. Moreland of Abbott Laboratories reports the disposition and acquisition of company stock, including shares sold to cover tax obligations.

Summary

• Mary K. Moreland, an Executive Vice President at Abbott Laboratories, filed a Form 4 detailing changes in her beneficial ownership of Abbott stock.
• On February 28, 2025, 5,598 common shares were disposed of at a price of $135.87 per share.
• This disposition was likely to cover tax obligations related to stock awards.
• On March 3, 2025, 791 common shares were sold at $138.17 per share.
• Following these transactions, Moreland directly owns 95,583 common shares.
• She also indirectly owns 11,623 shares through a Profit Sharing Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock transactions are common across publicly traded companies like Abbott Laboratories.
• Similar filings are made by executives at companies like Johnson & Johnson (JNJ) and Pfizer (PFE).
• The scale of these transactions is typical for executives holding significant equity in their companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares traded relative to the company's overall market capitalization.

Key Dates